Quantcast

Latest Prostate-specific antigen Stories

2014-09-18 08:29:25

Key evaluation to inform the US Food and Drug Administration regulatory submission SYDNEY, Sept. 18, 2014 /PRNewswire/ -- Australian biomarker discovery company Minomic International Ltd will today launch an important US trial of its MiStat(TM) prostate cancer screening test, planning to achieve US Food and Drug Administration (FDA) regulatory approval upon completion. Minomic's proprietary MiStat(TM) technology is a screening assay capable of identifying the presence of a...

2014-09-17 08:30:32

Proprietary genomic-based VPAC1 cancer biomarker to be co-developed worldwide? PARK CITY, Utah, Sept. 17, 2014 /PRNewswire/ -- NuView Life Sciences, Inc. (NuView) announced entry into an exclusive global licensing and collaboration agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka) to further develop and commercialize NuView's investigative genomic-based diagnostic biomarker to detect cancers of the breast and prostate. The agreement also includes all other future...

2014-09-11 12:27:33

SANTA MONICA, Calif., Sept. 11, 2014 /PRNewswire-USNewswire/ -- The Prostate Cancer Foundation (PCF) has awarded 27 new Young Investigator Awards selected from 16 countries to advance new drug discovery, immunotherapy, nutritional sciences, and diagnostics for precision medicine. Young Investigator (YI) Awards stand out among PCF's prestigious research programs, and serve to jumpstart the research careers of recent MDs and PhDs. These 3-year awards are game-changing investments that...

2014-09-09 08:31:59

SAN ANTONIO, Sept. 9, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCBB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, today announced that the United States Patent and Trademark Office (USPTO) issued patent 8,822,406 "Tumor Activated Prodrugs." The patent covers the composition of a specific prodrug activated by Prostate Specific Antigen (PSA) that is designed to deliver a thapsigargin derivative selectively to prostate cancers. PSA is an enzyme...

2014-09-09 08:31:36

Additional Data Acceptances Include Multiple Oncotype DX® Studies in Breast and Renal Cancers REDWOOD CITY, Calif., Sept. 9, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that results from nine studies of Oncotype DX(®) in prostate, breast and renal cancers will be presented at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, September 26 - 30. Included in the program is the first presentation of strongly positive results from an...

2014-09-03 08:32:58

Prostate Cancer Awareness Month in September Promotes Importance of Early Detection to Save Men's Lives MELVILLE, N.Y., Sept. 3, 2014 /PRNewswire/ -- Henry Schein Cares, the global corporate social responsibility program of Henry Schein, Inc., and the Large Urology Group Practice Association (LUGPA) have partnered again this year to raise awareness among families across the country about the importance of putting prostate cancer check-ups on the calendar for the men in their lives....

2014-09-02 12:29:05

LUGPA and ZERO Urge Men to Man Up and Go to the Doctor WASHINGTON, Sept. 2, 2014 /PRNewswire-USNewswire/ -- Today, at the start of National Prostate Health Month (NPHM), professional association representing urology practices in the United States, LUGPA, and patient advocate organization, ZERO - The End of Prostate Cancer, urged patients to man up and go to the doctor. "Prostate cancer is one of the most common cancers among men in the United States," said Juan Reyna, M.D.,...

2014-08-07 16:28:34

17% Increase in Test Volume, 11% Increase in Total Revenue and 29% Increase in International Product Revenue Compared to Prior Year REDWOOD CITY, Calif., Aug. 7, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter ended June 30, 2014. Product revenue was $70.5 million in the second quarter of 2014, compared with $63.7 million for the second quarter of 2013, an increase of 11 percent. There was no contract revenue in...

2014-08-06 08:31:58

Study Achieved Primary Endpoint of Predicting Recurrence after Surgery and Reconfirmed Original Adverse Pathology Endpoint from Published UCSF Validation Study REDWOOD CITY, Calif., Aug. 6, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced positive preliminary results from an additional independent clinical validation study conducted by the Center for Prostate Disease Research (CPDR) demonstrating that the Oncotype DX(®) Genomic Prostate Score (GPS) predicts...

2014-08-05 12:31:41

Active Surveillance Provides Low-Risk Patients Less Harmful Treatment Option NORTHFIELD, Ill., Aug. 5, 2014 /PRNewswire-USNewswire/ -- Prostate cancer is the second leading cause of cancer death in men in the United States. Active surveillance offers low-risk prostate cancer patients a means to avoid the potentially harmful side effects from treatment. Pathologists help determine patient eligibility for active surveillance and today a multi-specialty team published their recommendations for...


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related